- Pfizer und BioNTech erhalten positive CHMP-Empfehlung für an Omikron JN.1 angepassten COVID-19-Impfstoff in der Europäischen Union
- Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union
- BioNTech und DualityBio erhalten Fast-Track-Status der FDA für Antikörper-Wirkstoff-Konjugat-Kandidat BNT324/DB-1311 bei Prostatakrebs
- BioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug Conjugate Candidate BNT324/DB-1311 in Prostate Cancer
- Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
- Phase-2-Daten für Prüfpräparat Acasunlimab (DuoBody® -PD-L1x4-1BB) in Kombination mit Pembrolizumab: Signifikante klinische Aktivität bei vorbehandeltem, metastasiertem nicht-kleinzelligem Lungenkarzinom
- BioNTech and CEPI Expand Partnership to Strengthen Africa’s mRNA Vaccine Ecosystem
- BioNTech und CEPI erweitern Partnerschaft zur Stärkung des afrikanischen mRNA-Impfstoff-Ökosystems
- BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO Annual Meeting 2024
- BioNTech präsentiert auf der ASCO-Jahrestagung 2024 klinische Daten-Updates zu innovativen Immuntherapie-Kandidaten
More ▼
Key statistics
As of last trade Biontech SE (22UA:MUN) traded at 74.20, 1.64% above its 52-week low of 73.00, set on Jul 03, 2024.
52-week range
Open | 74.50 |
---|---|
High | 75.40 |
Low | 74.20 |
Bid | 74.10 |
Offer | 74.20 |
Previous close | 74.00 |
Average volume | 11.33k |
---|---|
Shares outstanding | 237.73m |
Free float | 214.95m |
P/E (TTM) | 155.39 |
Market cap | 19.04bn USD |
EPS (TTM) | 0.5154 USD |
Data delayed at least 15 minutes, as of Jul 08 2024 15:25 BST.
More ▼